Drug Profile
Berberine ursodeoxycholate - HighTide Biopharma
Alternative Names: BUDCA - HighTide Biopharma; HTD-1801Latest Information Update: 07 Nov 2023
Price :
$50
*
At a glance
- Originator HighTide Biopharma
- Class Anti-inflammatories; Antihyperglycaemics; Antihyperlipidaemics; Dioxolanes; Ethers; Hepatoprotectants; Heterocyclic compounds with 4 or more rings; Isoquinolines; Phenanthrenes; Small molecules
- Mechanism of Action Lipid modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Type 2 diabetes mellitus
- Phase II Hypercholesterolaemia; Non-alcoholic steatohepatitis; Primary biliary cirrhosis; Primary sclerosing cholangitis
Most Recent Events
- 02 Oct 2023 Efficacy and adverse events data from a phase II trial in Type 2 diabetes mellitus presented at the 59th Annual Meeting of the European Association for the Study of Diabetes (EASD-2023)
- 02 Oct 2023 HighTide Biopharma plans a phase III trial for Type 2 diabetes mellitus
- 20 Jul 2023 Phase-III clinical trials in Type 2 diabetes mellitus (PO), prior to July 2023 (HighTide Therapeutics pipeline, November 2021)